Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation

Significance The chemokine receptor axis plays a critical role in numerous physiological and pathological processes, yet the structural basis of receptor interaction with chemokines is poorly understood. Although the community agrees on the existence of two distinct epitopes for recognition of receptors by chemokines, conflicting evidence from structural and mutagenesis studies suggested several possibilities for receptor:chemokine complex stoichiometry. We use a combination of computational, functional, and biophysical approaches to show that despite its dimeric nature, chemokine receptor CXCR4 interacts with its chemokine ligand, CXCL12, in a 1:1 stoichiometry. This result is also likely relevant for other receptor:chemokine pairs. Structural modeling informed by restraints derived from cysteine trapping experiments enabled determination of the receptor:chemokine complex geometry at a medium resolution level. Chemokines and their receptors regulate cell migration during development, immune system function, and in inflammatory diseases, making them important therapeutic targets. Nevertheless, the structural basis of receptor:chemokine interaction is poorly understood. Adding to the complexity of the problem is the persistently dimeric behavior of receptors observed in cell-based studies, which in combination with structural and mutagenesis data, suggest several possibilities for receptor:chemokine complex stoichiometry. In this study, a combination of computational, functional, and biophysical approaches was used to elucidate the stoichiometry and geometry of the interaction between the CXC-type chemokine receptor 4 (CXCR4) and its ligand CXCL12. First, relevance and feasibility of a 2:1 stoichiometry hypothesis was probed using functional complementation experiments with multiple pairs of complementary nonfunctional CXCR4 mutants. Next, the importance of dimers of WT CXCR4 was explored using the strategy of dimer dilution, where WT receptor dimerization is disrupted by increasing expression of nonfunctional CXCR4 mutants. The results of these experiments were supportive of a 1:1 stoichiometry, although the latter could not simultaneously reconcile existing structural and mutagenesis data. To resolve the contradiction, cysteine trapping experiments were used to derive residue proximity constraints that enabled construction of a validated 1:1 receptor:chemokine model, consistent with the paradigmatic two-site hypothesis of receptor activation. The observation of a 1:1 stoichiometry is in line with accumulating evidence supporting monomers as minimal functional units of G protein-coupled receptors, and suggests transmission of conformational changes across the dimer interface as the most probable mechanism of altered signaling by receptor heterodimers.

[1]  T. Hara,et al.  CXCL14 is a natural inhibitor of the CXCL12–CXCR4 signaling axis , 2013, FEBS letters.

[2]  Mette M. Rosenkilde,et al.  Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.

[3]  J. Wess,et al.  Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[5]  Adam J Kuszak,et al.  Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2. , 2009, The Journal of biological chemistry.

[6]  Dan Li,et al.  Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches. , 2013, Molecular bioSystems.

[7]  Michel Bouvier,et al.  Bioluminescence Resonance Energy Transfer Reveals Ligand-induced Conformational Changes in CXCR4 Homo- and Heterodimers* , 2005, Journal of Biological Chemistry.

[8]  B. Sykes,et al.  Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.

[9]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[10]  T. Jin,et al.  Fluorescence Resonance Energy Transfer Imaging Reveals that Chemokine-Binding Modulates Heterodimers of CXCR4 and CCR5 Receptors , 2008, PloS one.

[11]  J. Qian,et al.  Visualization of arrestin recruitment by a G Protein-Coupled Receptor , 2014, Nature.

[12]  Dominique Schols,et al.  Mutations at the CXCR4 interaction sites for AMD3100 influence anti‐CXCR4 antibody binding and HIV‐1 entry , 2003, FEBS letters.

[13]  M. Parmentier,et al.  Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the Protean Effects of “Selective” Antagonists* , 2009, The Journal of Biological Chemistry.

[14]  Leigh A. Stoddart,et al.  Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  G. Milligan The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization , 2013, Molecular Pharmacology.

[16]  N. Heveker,et al.  Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities* , 2000, The Journal of Biological Chemistry.

[17]  Dominique Schols,et al.  Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor* , 2007, Journal of Biological Chemistry.

[18]  Won-Tak Choi,et al.  Unique Ligand Binding Sites on CXCR4 Probed by a Chemical Biology Approach: Implications for the Design of Selective Human Immunodeficiency Virus Type 1 Inhibitors , 2005, Journal of Virology.

[19]  Pierre Corvol,et al.  Polar Residues in the Transmembrane Domains of the Type 1 Angiotensin II Receptor Are Required for Binding and Coupling , 1996, The Journal of Biological Chemistry.

[20]  T. Handel,et al.  Chemokine receptor oligomerization and allostery. , 2013, Progress in molecular biology and translational science.

[21]  Cristina Limatola,et al.  Ligand-independent CXCR2 Dimerization* , 2003, Journal of Biological Chemistry.

[22]  R. Wong,et al.  Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors , 2008, Molecular Pharmacology.

[23]  Garland R Marshall,et al.  Insight into the Binding Mode for Cyclopentapeptide Antagonists of the CXCR4 Receptor , 2006, Chemical biology & drug design.

[24]  T. Sakmar,et al.  CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration* , 2011, The Journal of Biological Chemistry.

[25]  R. Gorlin,et al.  Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.

[26]  Mudit Gupta,et al.  Imaging chemokine receptor dimerization with firefly luciferase complementation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  M. Simon,et al.  G alpha 15 and G alpha 16 couple a wide variety of receptors to phospholipase C. , 1995, The Journal of biological chemistry.

[28]  N. Heveker,et al.  AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties , 2009, Molecular Pharmacology.

[29]  T. Schall,et al.  Elucidation of CXCR7-Mediated Signaling Events and Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migration by CXCR7 Ligands , 2009, The Journal of Immunology.

[30]  Masahiko Kuroda,et al.  Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.

[31]  Ruben Abagyan,et al.  Compound activity prediction using models of binding pockets or ligand properties in 3D. , 2012, Current topics in medicinal chemistry.

[32]  Hideo Takahashi,et al.  Structural Basis of the Interaction between Chemokine Stromal Cell-derived Factor-1/CXCL12 and Its G-protein-coupled Receptor CXCR4* , 2009, The Journal of Biological Chemistry.

[33]  Graeme Milligan,et al.  Domain Swapping in the Human Histamine H1 Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[34]  J. Pin,et al.  Activation of a Dimeric Metabotropic Glutamate Receptor by Intersubunit Rearrangement* , 2007, Journal of Biological Chemistry.

[35]  Albert Zlotnik,et al.  Homeostatic chemokine receptors and organ-specific metastasis , 2011, Nature Reviews Immunology.

[36]  R. Abagyan,et al.  Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.

[37]  Gregory J Babcock,et al.  Ligand-independent Dimerization of CXCR4, a Principal HIV-1 Coreceptor* , 2003, The Journal of Biological Chemistry.

[38]  Richard N. Zare,et al.  A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein , 2007, Proceedings of the National Academy of Sciences.

[39]  F. Baleux,et al.  CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. , 2009, Blood.

[40]  Tullio Pozzan,et al.  CXCR4–CCR5: A couple modulating T cell functions , 2008, Proceedings of the National Academy of Sciences.

[41]  N. Heveker,et al.  Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways , 2011, Proceedings of the National Academy of Sciences.

[42]  R. Abagyan,et al.  A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer. , 2013, Methods in molecular biology.

[43]  E. De Clercq,et al.  Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.

[44]  T. Schall,et al.  The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells , 2011, Molecular Cancer.

[45]  T. Handel,et al.  Modulation of chemokine receptor activity through dimerization and crosstalk , 2009, Cellular and Molecular Life Sciences.

[46]  R. Bronson,et al.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Tai,et al.  Expression and functional characterization of mutant human CXCR4 in insect cells: role of cysteinyl and negatively charged residues in ligand binding. , 2000, Archives of biochemistry and biophysics.

[48]  F. Baleux,et al.  CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. , 2008, Blood.

[49]  S. Sligar,et al.  Monomeric Rhodopsin Is Sufficient for Normal Rhodopsin Kinase (GRK1) Phosphorylation and Arrestin-1 Binding* , 2010, The Journal of Biological Chemistry.

[50]  Marc Parmentier,et al.  Allosteric Transinhibition by Specific Antagonists in CCR2/CXCR4 Heterodimers* , 2007, Journal of Biological Chemistry.

[51]  W. Fischer,et al.  In Silico Analysis Reveals Sequential Interactions and Protein Conformational Changes during the Binding of Chemokine CXCL-8 to Its Receptor CXCR1 , 2014, PloS one.

[52]  N. V. van Nuland,et al.  Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. , 2012, Biochemical pharmacology.

[53]  B. Sykes,et al.  Neutrophil activation by monomeric interleukin-8. , 1994, Science.

[54]  M. Simon,et al.  Gα15 and Gα16 Couple a Wide Variety of Receptors to Phospholipase C (*) , 1995, The Journal of Biological Chemistry.

[55]  A. Marchese,et al.  CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin* , 2010, The Journal of Biological Chemistry.

[56]  Mario Mellado,et al.  Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways , 2001, The EMBO journal.

[57]  Kuan-Teh Jeang,et al.  Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.

[58]  Christoph Seibert,et al.  Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12 , 2008, Science Signaling.

[59]  L. Hunyady,et al.  Allosteric interactions within the AT₁ angiotensin receptor homodimer: role of the conserved DRY motif. , 2012, Biochemical pharmacology.

[60]  Krzysztof Palczewski,et al.  Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.

[61]  R. Leurs,et al.  Pharmacological modulation of chemokine receptor function , 2012, British journal of pharmacology.

[62]  R. Ghirlando,et al.  Modulation of the interaction between neurotensin receptor NTS1 and Gq protein by lipid. , 2012, Journal of molecular biology.

[63]  M. Farzan,et al.  The Role of Post-translational Modifications of the CXCR4 Amino Terminus in Stromal-derived Factor 1α Association and HIV-1 Entry* , 2002, The Journal of Biological Chemistry.

[64]  R. Abagyan,et al.  Soft protein–protein docking in internal coordinates , 2002, Protein science : a publication of the Protein Society.

[65]  R. Koenen,et al.  Heterophilic chemokine receptor interactions in chemokine signaling and biology. , 2011, Experimental cell research.

[66]  Nafis Rahman,et al.  Rescue of defective G protein–coupled receptor function in vivo by intermolecular cooperation , 2010, Proceedings of the National Academy of Sciences.

[67]  J. Trejo,et al.  Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling* , 2013, The Journal of Biological Chemistry.

[68]  P. Toth,et al.  Regulation of CXCR4 Receptor Dimerization by the Chemokine SDF-1α and the HIV-1 Coat Protein gp120: A Fluorescence Resonance Energy Transfer (FRET) Study , 2004, Journal of Pharmacology and Experimental Therapeutics.

[69]  Ruben Abagyan,et al.  Role of 3D Structures in Understanding, Predicting, and Designing Molecular Interactions in the Chemokine Receptor Family , 2014 .

[70]  B. Volkman,et al.  The CXC Chemokine Receptor 4 Ligands Ubiquitin and Stromal Cell-derived Factor-1α Function through Distinct Receptor Interactions* , 2011, The Journal of Biological Chemistry.

[71]  Krzysztof Palczewski,et al.  Efficient Coupling of Transducin to Monomeric Rhodopsin in a Phospholipid Bilayer* , 2008, Journal of Biological Chemistry.

[72]  Andrea Iaboni,et al.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer , 2006, Nature Methods.

[73]  R. Abagyan,et al.  Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists , 2010, Science.

[74]  N. Aiyar,et al.  Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1alpha: implications for development of selective CXCR4 antagonists. , 2001, Immunology letters.

[75]  Allen P. Liu,et al.  Multiplex Detection of Homo- and Heterodimerization of G Protein-Coupled Receptors by Proximity Biotinylation , 2014, PloS one.

[76]  D. Sinnett,et al.  The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. , 2010, The Journal of biological chemistry.

[77]  Maxim Totrov,et al.  Atomic Property Fields: Generalized 3D Pharmacophoric Potential for Automated Ligand Superposition, Pharmacophore Elucidation and 3D QSAR , 2007, Chemical biology & drug design.

[78]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[79]  Won-Tak Choi,et al.  Distinct Functional Sites for Human Immunodeficiency Virus Type 1 and Stromal Cell-Derived Factor 1α on CXCR4 Transmembrane Helical Domains , 2005, Journal of Virology.

[80]  F. Hamdan,et al.  Monitoring Protein‐Protein Interactions in Living Cells by Bioluminescence Resonance Energy Transfer (BRET) , 2006, Current protocols in neuroscience.

[81]  J. Sodroski,et al.  A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry. , 2012, Biochemistry.

[82]  T. Handel,et al.  Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery. , 2013, ACS chemical biology.

[83]  Zhaowen Luo,et al.  Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies* , 2001, The Journal of Biological Chemistry.

[84]  T. Schwartz,et al.  Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor* , 2001, The Journal of Biological Chemistry.

[85]  M. Parmentier,et al.  Evidence for Negative Binding Cooperativity within CCR5-CCR2b Heterodimers , 2005, Molecular Pharmacology.